These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 30020783)

  • 1. Structure-Function Analysis of Immune Checkpoint Receptors to Guide Emerging Anticancer Immunotherapy.
    Acúrcio RC; Scomparin A; Conniot J; Salvador JAR; Satchi-Fainaro R; Florindo HF; Guedes RC
    J Med Chem; 2018 Dec; 61(24):10957-10975. PubMed ID: 30020783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rational design of anti-GITR-based combination immunotherapy.
    Zappasodi R; Sirard C; Li Y; Budhu S; Abu-Akeel M; Liu C; Yang X; Zhong H; Newman W; Qi J; Wong P; Schaer D; Koon H; Velcheti V; Hellmann MD; Postow MA; Callahan MK; Wolchok JD; Merghoub T
    Nat Med; 2019 May; 25(5):759-766. PubMed ID: 31036879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of action of therapeutic antibodies for cancer.
    Redman JM; Hill EM; AlDeghaither D; Weiner LM
    Mol Immunol; 2015 Oct; 67(2 Pt A):28-45. PubMed ID: 25911943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy.
    Babamohamadi M; Mohammadi N; Faryadi E; Haddadi M; Merati A; Ghobadinezhad F; Amirian R; Izadi Z; Hadjati J
    Cell Death Dis; 2024 Jan; 15(1):17. PubMed ID: 38191571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small-molecule modulators of tumor immune microenvironment.
    Zhang J; Yu J; Liu M; Xie Z; Lei X; Yang X; Huang S; Deng X; Wang Z; Tang G
    Bioorg Chem; 2024 Apr; 145():107251. PubMed ID: 38442612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma.
    Rodig SJ; Gusenleitner D; Jackson DG; Gjini E; Giobbie-Hurder A; Jin C; Chang H; Lovitch SB; Horak C; Weber JS; Weirather JL; Wolchok JD; Postow MA; Pavlick AC; Chesney J; Hodi FS
    Sci Transl Med; 2018 Jul; 10(450):. PubMed ID: 30021886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy.
    Wang LL; Patel G; Chiesa-Fuxench ZC; McGettigan S; Schuchter L; Mitchell TC; Ming ME; Chu EY
    JAMA Dermatol; 2018 Sep; 154(9):1057-1061. PubMed ID: 30027278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma.
    Johnson DB; Bordeaux J; Kim JY; Vaupel C; Rimm DL; Ho TH; Joseph RW; Daud AI; Conry RM; Gaughan EM; Hernandez-Aya LF; Dimou A; Funchain P; Smithy J; Witte JS; McKee SB; Ko J; Wrangle JM; Dabbas B; Tangri S; Lameh J; Hall J; Markowitz J; Balko JM; Dakappagari N
    Clin Cancer Res; 2018 Nov; 24(21):5250-5260. PubMed ID: 30021908
    [No Abstract]   [Full Text] [Related]  

  • 9. Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration.
    Oweida A; Hararah MK; Phan A; Binder D; Bhatia S; Lennon S; Bukkapatnam S; Van Court B; Uyanga N; Darragh L; Kim HM; Raben D; Tan AC; Heasley L; Clambey E; Nemenoff R; Karam SD
    Clin Cancer Res; 2018 Nov; 24(21):5368-5380. PubMed ID: 30042205
    [No Abstract]   [Full Text] [Related]  

  • 10. Immune check point inhibitors for metastatic urothelial carcinoma: current evidence-based approach for urology daily practice.
    Nabar ND; Brandt MP; Thomas C; Tsaur I; Bartsch G; Jaeger W; Haferkamp A; Höfner T
    Minerva Urol Nefrol; 2019 Jun; 71(3):205-216. PubMed ID: 30021426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic testing of stimulative and suppressive biomarkers on peripheral blood cells at early stages of immunotherapy predicts response in advanced cancer patients.
    Du W; Hu S; Cai S; Wang Y; Wu L; Sun D; Jiao S; Hu Y
    Discov Med; 2018 Jun; 25(140):277-290. PubMed ID: 30021101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel, Fully Human Anti-fucosyl-GM1 Antibody Demonstrates Potent
    Ponath P; Menezes D; Pan C; Chen B; Oyasu M; Strachan D; LeBlanc H; Sun H; Wang XT; Rangan VS; Deshpande S; Cristea S; Park KS; Sage J; Cardarelli PM
    Clin Cancer Res; 2018 Oct; 24(20):5178-5189. PubMed ID: 30021910
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical Characteristics of Liver Metastasis in Nivolumab-treated Patients with Non-small Cell Lung Cancer.
    Shiroyama T; Suzuki H; Tamiya M; Tamiya A; Tanaka A; Okamoto N; Nakahama K; Taniguchi Y; Isa SI; Inoue T; Imamura F; Atagi S; Hirashima T
    Anticancer Res; 2018 Aug; 38(8):4723-4729. PubMed ID: 30061241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy.
    Siegel J; Totonchy M; Damsky W; Berk-Krauss J; Castiglione F; Sznol M; Petrylak DP; Fischbach N; Goldberg SB; Decker RH; Stamatouli AM; Hafez N; Glusac EJ; Tomayko MM; Leventhal JS
    J Am Acad Dermatol; 2018 Dec; 79(6):1081-1088. PubMed ID: 30025829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer.
    Kulangara K; Zhang N; Corigliano E; Guerrero L; Waldroup S; Jaiswal D; Ms MJ; Shah S; Hanks D; Wang J; Lunceford J; Savage MJ; Juco J; Emancipator K
    Arch Pathol Lab Med; 2019 Mar; 143(3):330-337. PubMed ID: 30028179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineering PD-1-Presenting Platelets for Cancer Immunotherapy.
    Zhang X; Wang J; Chen Z; Hu Q; Wang C; Yan J; Dotti G; Huang P; Gu Z
    Nano Lett; 2018 Sep; 18(9):5716-5725. PubMed ID: 30063143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Characterization of Peptide Ligands of Immunoglobulin G Fc Region.
    Kruljec N; Molek P; Hodnik V; Anderluh G; Bratkovič T
    Bioconjug Chem; 2018 Aug; 29(8):2763-2775. PubMed ID: 30024737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Ubiquitin Ligase Adaptor NDFIP1 Selectively Enforces a CD8
    Wagle MV; Marchingo JM; Howitt J; Tan SS; Goodnow CC; Parish IA
    Cell Rep; 2018 Jul; 24(3):577-584. PubMed ID: 30021156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response.
    Chen G; Huang AC; Zhang W; Zhang G; Wu M; Xu W; Yu Z; Yang J; Wang B; Sun H; Xia H; Man Q; Zhong W; Antelo LF; Wu B; Xiong X; Liu X; Guan L; Li T; Liu S; Yang R; Lu Y; Dong L; McGettigan S; Somasundaram R; Radhakrishnan R; Mills G; Lu Y; Kim J; Chen YH; Dong H; Zhao Y; Karakousis GC; Mitchell TC; Schuchter LM; Herlyn M; Wherry EJ; Xu X; Guo W
    Nature; 2018 Aug; 560(7718):382-386. PubMed ID: 30089911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor Molecular Testing Guides Anti-PD-1 Therapy and Provides Evidence for Pathogenicity of Mismatch Repair Variants.
    Patel SA; Longacre TA; Ladabaum U; Lebensohn A; Lin AY; Haraldsdottir S
    Oncologist; 2018 Dec; 23(12):1395-1400. PubMed ID: 30072391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.